EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomarkers in Hemophilia: Diagnostic, Prognostic, and Treatment-Selection Utility: A Narrative Review of the Literature

Dalia Atef Abouda, Elsayed S. Moubarak, Fatma ElBadrawy, Malak A. Hassan, Mohamed Mohsen Helal, Abdallah M. Ibrahim, Hassan H. Eladl, Mohammad Mahadin, Mohamed Elsaid‎

ASIDE Internal Medicine · 2026

DOI: 10.71079/aside.im.022826376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ASIDE Internal Medicine, 2026. Verfasst von Dalia Atef Abouda und 8 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemophilia A and B are inherited bleeding disorders in which outcomes are shaped by factor levels, inhibitor development, inter-individual pharmacokinetics, and progressive joint disease. With the emergence of extended half-life therapies, non-factor therapies, and gene therapy, there is an increasing need for biomarkers to support diagnosis, risk stratification, treatment selection, and monitoring.

Methods

We conducted a narrative review of English-language studies indexed in PubMed, Scopus, Web of Science, and Google Scholar (January 2000 to October 2025). We prioritized primary studies, trials, registries, and assay-validation reports on diagnostic, prognostic, predictive, or monitoring biomarkers in hemophilia A/B; guidelines were used for context.

Results

Established biomarkers include FVIII/FIX activity assays, inhibitor testing (Bethesda/Nijmegen-modified), F8/F9 genotyping, and imaging-based joint assessment. Emerging candidates include global hemostasis assays (thrombin generation, viscoelastic testing), PK/PD metrics for prophylaxis individualization, and exploratory inflammatory/angiogenic and tissue-turnover markers linked to arthropathy.

Conclusions

Evidence for biomarkers in hemophilia is heterogeneous, and many non-traditional markers remain exploratory; standardized assays and prospective multicenter validation with clinically meaningful endpoints are needed before routine adoption. Limitation: This narrative synthesis was conducted in English and did not include a formal risk-of-bias assessment.

Zitieren

APA

Abouda, D. A., Moubarak, E. S., ElBadrawy, F., Hassan, M. A., Helal, M. M., Ibrahim, A. M., Eladl, H. H., Mahadin, M., & Elsaid‎, M. (2026). Biomarkers in Hemophilia: Diagnostic, Prognostic, and Treatment-Selection Utility: A Narrative Review of the Literature. ASIDE Internal Medicine. https://doi.org/10.71079/aside.im.022826376

Vancouver

Abouda DA, Moubarak ES, ElBadrawy F, Hassan MA, Helal MM, Ibrahim AM, et al. Biomarkers in Hemophilia: Diagnostic, Prognostic, and Treatment-Selection Utility: A Narrative Review of the Literature. ASIDE Internal Medicine. 2026. doi:10.71079/aside.im.022826376

BibTeX
@article{Abouda2026,
  author = {Abouda, Dalia Atef and Moubarak, Elsayed S. and ElBadrawy, Fatma and Hassan, Malak A. and Helal, Mohamed Mohsen and Ibrahim, Abdallah M. and Eladl, Hassan H. and Mahadin, Mohammad and Elsaid‎, Mohamed},
  title = {Biomarkers in Hemophilia: Diagnostic, Prognostic, and Treatment-Selection Utility: A Narrative Review of the Literature},
  journal = {ASIDE Internal Medicine},
  year = {2026},
  doi = {10.71079/aside.im.022826376}
}
Kostenlos starten →